North America Point-Care Molecular Testing for Infectious Diseases Market Size and Forecast (2021-2031)

According to our new research study on ” North America Point-Of-Care Molecular Testing For Infectious Diseases Market Size and Forecast (2021–2031), Regional Share, Trend, and Growth Opportunity Analysis,” the market value is projected to grow from US$ 1.09 billion in 2023 to US$ 2.63 billion by 2031. The North America point-of-care molecular testing for infectious diseases market is further anticipated to record a CAGR of 11.5% from 2022 to 2030. The surging prevalence of infectious diseases and preference for rapid diagnostic solutions are the key driving factors behind the market development. However, inadequate reimbursement scenario is hampering the market growth.

Infectious diseases adversely affect public health, causing morbidity, mortality, and economic burdens. The effective management, treatment, and prevention of these health conditions require accurate and timely diagnosis. Molecular diagnostics techniques, laboratory-based assays, and point-of-care tests are employed for the diagnosis of HIV, tuberculosis, and hepatitis C; human papillomavirus screening for cervical cancer; and the monitoring of health and treatment progress in patients. Healthcare providers turn to point-of-care testing to streamline diagnostic processes, reduce turnaround times, and enhance patient care. These tests also ease diagnoses during infectious disease outbreaks. According to data published by the CDC in 2022, Florida (US) suffered the onset of concurrent epidemics of hepatitis A, invasive meningococcal disease (IMD), and mpox (formerly known as monkeypox). Mpox cases were more strongly concentrated in South Florida and peaked in August. In contrast, the hepatitis A and IMD epidemics were centered in Central Florida and peaked from March to June. Nearly 2,845 cases of the mumps were reported in Florida as part of a worldwide outbreak. HIV infection was found in 52% of mpox patients compared to 21% of hepatitis A and 34% of IMD cases. These pathogens include hepatitis A, mpox, and meningococcal disease.

The reemergence of diseases such as tuberculosis, malaria, and hepatitis has necessitated the development of effective diagnostic tools to identify the causative agents and determine effective treatment regimens. According to the National Institutes of Health, 8,300 tuberculosis cases were reported in the US in 2022 compared to 7,874 cases reported in 2021. The incidence of tuberculosis rose a little from 2.4 per 100,000 people in 2021 to 2.5 per 100,000 persons in 2022. Thus, the surging prevalence of infectious disease propels the need for point-of-care testing over traditional techniques, such as microbial culture, hemagglutination inhibition tests, and enzyme-linked immunosorbent assays (ELISA). The COVID-19 pandemic further underlined the importance of rapid and accessible diagnostic testing for infectious diseases. The need for quick identification and containment of infectious pathogens propelled the demand for innovative point-of-care testing solutions in North America.

Based on disease, the North America point-of-care molecular testing for infectious diseases market is divided into HIV testing, influenza testing, sexually transmitted diseases testing, hepatitis C virus testing, tropical diseases testing, respiratory infection testing, hospital-acquired infections, strep, and others. The market is further divided on the basis of molecular diagnostics into polymerase chain reactions (PCR), isothermal nucleic acid amplification technology (INAAT), and others. The respiratory infection testing segment held the largest market share in 2023.

By technology, the market is segmented into lateral flow assay, dipsticks, microfluidics, molecular diagnostics, immunoassays, solid phase, and others. The lateral flow assay segment held the largest share of the market in 2023.

In terms of sample, the market is segmented into blood samples, urine samples, nasal and oropharyngeal swabs, and others. The blood sample segment held the largest market share in 2023.

In terms of end user, the market is segmented into hospitals and clinics, home care settings, ambulatory and urgent care facilities, nursing homes and assisted living facilities, research laboratories, and diagnostics centers. The market is further divided on the basis of hospitals and clinics into clinical laboratories, professional physician offices, and others. The hospitals and clinics segment held the largest market share in 2023.

Abbott Laboratories, Agilent Technologies Inc, Becton Dickinson and Co, Bio-Rad Laboratories Inc, Cardinal Health Inc, Danaher Corp, Cue Health Inc, QuidelOrtho Corp, Thermo Fisher Scientific Inc, and F. Hoffmann-La Roche Ltd. are a few key companies profiled in the North America point-of-care molecular testing for infectious diseases market report.

Companies operating in the North America point-of-care molecular testing for infectious diseases market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the North America point-of-care molecular testing for infectious diseases market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall North America point-of-care molecular testing for infectious diseases market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• In February 2023, Thermo Fisher Scientific collaborated with Mylab to source RT-PCR kits for the detection of multidrug-resistant Mycobacterium tuberculosis (MDR MTB), hepatitis B and C viruses, and HIV; genetic analysis of HLA B27; and so on.

• In August 2023, QuidelOrtho Corporation—a global supplier of cutting-edge in-vitro diagnostic technologies intended for clinical labs, point-of-care settings, and transfusion medicine—won FDA approval for its De Novo request, enabling the business to commercialize its new Sofia 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA became the first fast antigen test to receive FDA market clearance for COVID-19 detection. The test can be utilized in point-of-care settings and is only meant to be used with a prescription.

• In March 2022, Quest Diagnostics launched two post-COVID-19 panels to provide information on health problems that may persist after prior COVID-19 virus infections. According to Quest, the Post-COVID-19 Basic Panel and Post-COVID-19 Expanded Test Panel offers customers a more thorough examination of their health and aid in getting them ready for conversations with their healthcare providers.

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.3 Hypothesis formulation
3.3.1 Macro-economic factor analysis:
3.3.2 Developing base number:
3.3.3 Data Triangulation:
3.3.4 Country level data:
4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Landscape
4.1 Overview
4.2 PEST Analysis
5. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Key Market Dynamics
5.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Surging Prevalence of Infectious Diseases
5.2.2 Preference for Rapid Diagnostic Solutions
5.3 Market Restraints
5.3.1 Inadequate Reimbursement Scenario
5.4 Market Opportunities
5.4.1 Increasing Focus on R&D and Funding in Infectious Disease Diagnostics
5.5 Future Trends
5.5.1 Rising Number of Product Approvals and Launches
5.6 Impact of Drivers and Restraints:
6. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis
6.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021–2031
6.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Forecast and Analysis
6.3 Market Share Analysis, By Companies (2023)
6.4 Pricing Analysis
6.5 Pre and Post COVID-19 Impact
6.6 Intellectual Property Rights of Products/Companies
6.6.1 POC Patent Filing
6.7 Novel Companies Entering the Point of Care Testing Market For Infectious Diseases Application
7. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Diseases
7.1 HIV Testing
7.1.1 Overview
7.1.2 HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Influenza Testing
7.2.1 Overview
7.2.2 Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Sexually Transmitted Diseases Testing
7.3.1 Overview
7.3.2 Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.3.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing
7.4 Hepatitis C Virus Testing
7.4.1 Overview
7.4.2 Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Tropical Diseases Testing
7.5.1 Overview
7.5.2 Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.5.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing
7.6 Respiratory Infection Testing
7.6.1 Overview
7.6.2 Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Hospital Acquired Infections
7.7.1 Overview
7.7.2 Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.8 Strep
7.8.1 Overview
7.8.2 Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.9 Others
7.9.1 Overview
7.9.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Technology
8.1 Lateral Flow Assay
8.1.1 Overview
8.1.2 Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Dipsticks
8.2.1 Overview
8.2.2 Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Microfluidics
8.3.1 Overview
8.3.2 Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Molecular Diagnostics
8.4.1 Overview
8.4.2 Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.4.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics
8.4.2.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)
8.5 Immunoassays
8.5.1 Overview
8.5.2 Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Solid Phase
8.6.1 Overview
8.6.2 Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
9. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Prescription Testing
9.1 Prescription Based Testing
9.1.1 Overview
9.1.2 Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
9.2 OTC Testing
9.2.1 Overview
9.2.2 OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
10. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Sample
10.1 Blood Sample
10.1.1 Overview
10.1.2 Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Urine Sample
10.2.1 Overview
10.2.2 Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Nasal and Oropharyngeal Swabs Sample
10.3.1 Overview
10.3.2 Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
10.4 Others
10.4.1 Overview
10.4.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by End User
11.1 Hospitals and Clinics
11.1.1 Overview
11.1.2 Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals and Clinics
11.2 Home Care Settings
11.2.1 Overview
11.2.2 Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11.3 Ambulatory and Urgent Care Facilities
11.3.1 Overview
11.3.2 Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11.4 Nursing Home and Assisted Living Facilities
11.4.1 Overview
11.4.2 Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11.5 Research Laboratories
11.5.1 Overview
11.5.2 Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11.6 Diagnostics Centers
11.6.1 Overview
11.6.2 Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
12. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Distribution Channel
12.1 E-Com Platforms
12.1.1 Overview
12.1.2 E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
12.2 Retail Channel and Pharmacies
12.2.1 Overview
12.2.2 Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
12.3 Others
12.3.1 Overview
12.3.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
13. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Country Analysis
13.1 North America
13.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Countries
13.1.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis – by Country
13.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis – by Country
13.1.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
13.1.2.2.1 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
13.1.2.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
13.1.2.2.3 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
13.1.2.2.4 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
13.1.2.2.5 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
13.1.2.2.6 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
13.1.2.2.7 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
13.1.2.2.8 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
13.1.2.2.9 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
13.1.2.2.10 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
13.1.2.2.11 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
13.1.2.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
13.1.2.3.1 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
13.1.2.3.2 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
13.1.2.3.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
13.1.2.3.4 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
13.1.2.3.5 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
13.1.2.3.6 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
13.1.2.3.7 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
13.1.2.3.8 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
13.1.2.3.9 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
13.1.2.3.10 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
13.1.2.3.11 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
13.1.2.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
13.1.2.4.1 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
13.1.2.4.2 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
13.1.2.4.3 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
13.1.2.4.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
13.1.2.4.5 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
13.1.2.4.6 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
13.1.2.4.7 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
13.1.2.4.8 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
13.1.2.4.9 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
13.1.2.4.10 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
13.1.2.4.11 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
14. North America Point-Of-Care Molecular Testing for Infectious Diseases Market – Industry Landscape
14.1 Overview
14.2 Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
14.3 Organic Growth Strategies
14.3.1 Overview
14.4 Inorganic Growth Strategies
14.4.1 Overview
15. Company Profiles
15.1 Abbott Laboratories
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Agilent Technologies Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Becton Dickinson and Co
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Bio-Rad Laboratories Inc
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 Cardinal Health Inc
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 Danaher Corp
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Cue Health Inc
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 QuidelOrtho Corp
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Thermo Fisher Scientific Inc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 F. Hoffmann-La Roche Ltd
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
16. Appendix
16.1 About the Research Team
16.2 Glossary of Terms

1.1.1

Table 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation
Table 2. Infectious Diseases and Fundings
Table 3. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Table 4. Market Share Analysis, By Companies (2023)
Table 5. Pricing Analysis
Table 6. List of Patent filed by Companies
Table 7. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases
Table 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing
Table 9. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing
Table 10. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology
Table 11. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics
Table 12. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)
Table 13. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing
Table 14. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample
Table 15. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 16. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals and Clinics
Table 17. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Country
Table 19. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases
Table 20. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing
Table 21. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing
Table 22. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology
Table 23. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics
Table 24. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)
Table 25. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing
Table 26. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample
Table 27. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 28. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals And Clinics
Table 29. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 30. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases
Table 31. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing
Table 32. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing
Table 33. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology
Table 34. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics
Table 35. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)
Table 36. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing
Table 37. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample
Table 38. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 39. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals And Clinics
Table 40. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 41. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases
Table 42. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing
Table 43. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing
Table 44. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology
Table 45. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics
Table 46. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)
Table 47. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing
Table 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample
Table 49. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 50. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals And Clinics
Table 51. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 52. Recent Organic Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
Table 53. Recent Inorganic Growth Strategies in the North America Point-Of-Care Molecular Testing For Infectious Diseases Market
Table 54. Glossary of Terms, Infectious Disease Diagnostics Market

1.1.2

Figure 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation, by Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021–2031
Figure 5. Pre and Post COVID-19 Impact
Figure 6. Patents filed by Top Companies for POC
Figure 7. Number of Patent Families for POC
Figure 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Diseases, 2023 and 2031
Figure 9. HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 17. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Technology, 2023 and 2031
Figure 19. Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 25. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 26. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Prescription Testing, 2023 and 2031
Figure 27. Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 29. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Sample, 2023 and 2031
Figure 30. Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 31. Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 32. Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 33. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 34. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by End User, 2023 and 2031
Figure 35. Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 36. Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 37. Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 38. Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 39. Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 40. Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 41. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Distribution Channel, 2023 and 2031
Figure 42. E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 43. Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 44. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 45. North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 46. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 47. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 49. Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market